Gilead Sciences (GILD) Interest Expenses (2009 - 2026)
Gilead Sciences' (GILD) quarterly Interest Expenses came in at $247.0 million in Q2 2026, down 2.76% on a YoY basis from $254.0 million in Q2 2025, and up 2.92% quarter-over-quarter from $240.0 million in Q1 2026.
Analysis
Gilead Sciences (GILD) Interest Expenses (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Interest Expenses for 18 consecutive years, with $247.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest Expenses fell 2.76% year-over-year to $247.0 million; the trailing twelve-month figure through Jun 2026 stood at $998.0 million (changed 0.3% YoY), and the FY2025 full-year result was $1.0 billion, up 4.81% from the prior year.
- Interest Expenses climbed to $247.0 million in Q2 2026 per GILD's latest filing, from $240.0 million in the prior quarter.
- Across five years, Interest Expenses topped out at $260.0 million in Q1 2025 and bottomed at $226.0 million in Q4 2022.
- Historically, Interest Expenses has averaged $242.7 million across 5 years, with a median of $241.0 million in 2022.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses dropped 8.4% in 2022, then grew 11.5% in 2023.
- Over 5 years, Interest Expenses stood at $226.0 million in 2022, then increased by 11.5% to $252.0 million in 2023, then declined by 1.19% to $249.0 million in 2024, then gained by 2.41% to $255.0 million in 2025, then declined by 3.14% to $247.0 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $247.0 million, $240.0 million, and $255.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.26 Bn | 193.27 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.66 Bn | 176.48 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.52 Bn | 123.67 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.77 Bn | 73.78 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.15 Bn | 55.97 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.55 Bn | 48.41 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.38 Bn | 30.07 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.68 Bn | 30.40 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.12 Bn | 29.12 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.69 Bn | 26.53 Bn | 358.27 Mn | 20.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 247.00 Mn |
| Mar 31, 2026 | 240.00 Mn |
| Dec 31, 2025 | 255.00 Mn |
| Sep 30, 2025 | 256.00 Mn |
| Jun 30, 2025 | 254.00 Mn |
| Mar 31, 2025 | 260.00 Mn |
| Dec 31, 2024 | 249.00 Mn |
| Sep 30, 2024 | 238.00 Mn |
| Jun 30, 2024 | 237.00 Mn |
| Mar 31, 2024 | 254.00 Mn |
| Dec 31, 2023 | 252.00 Mn |
| Sep 30, 2023 | 232.00 Mn |
| Jun 30, 2023 | 230.00 Mn |
| Mar 31, 2023 | 230.00 Mn |
| Dec 31, 2022 | 226.00 Mn |
| Sep 30, 2022 | 229.00 Mn |
| Jun 30, 2022 | 242.00 Mn |
| Mar 31, 2022 | 238.00 Mn |
| Dec 31, 2021 | 238.00 Mn |
| Sep 30, 2021 | 250.00 Mn |